N/A N=102 Iron Parameters in Non-anemic First Trimester Gravidas
Iron Deficiency (Without Anemia) · Pregnancy
Primary: Percent of Non-anemic Patients With Iron Deficiency Stratified by Gravidity — 9; 3; 6; 38 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=56 Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)
Anemia
Primary: Change in Left Ventricular End-diastolic Volume — -6; -4 mL
Phase 2 N=100 Practical Anemia Bundle for SusTained Blood Recovery
Anemia · Critical Illness
Primary: Hemoglobin Concentrations — 11.5; 12.2 g/dL — p=0.02
Phase 3 N=594 Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis
Anemia in Chronic Kidney Disease in Non-dialysis Patients
Primary: Percentage of Participants With a Hemoglobin (Hb) Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy Prior to…
N/A N=809 Is Iron Deficiency the Cause of Anemia Among Women in Cambodia?
Anemia · Iron Deficiency · Hemoglobin Disorder
Primary: Hemoglobin Levels at 12-weeks. Marginal Means (95% CI). — 123; 116; 121; 116 g/L — p=<0.05
Phase 3 N=402 Sub-clinical Inflammation and Iron Supplementation
Anemia
Primary: Haemoglobin Level — 88.3; 89.2; 88.4; 89.6 g/L — p=<0.05
Phase 3 N=51 Daily vs. Every Other Day Oral Iron Supplementation in Patients With Absolute Iron Deficiency Anemia
Anemia · Iron Deficiency Anemia
Primary: Feasibility of Enrolling Patients in the Trial — 85 participants
N/A N=851 Association of Anemia With Hospital Costs in Elective Colorectal Surgery
Surgery · Surgical Blood Loss · Anemia
Primary: Total Hospital Costs — 23,667; 17,100 Dollars
N/A N=146 Analyses of Anemia in Very Low Birth Weight (VLBW) Infants.
Very Preterm Maturity of Infant · The Risk Factors for Improving the Prognosis of VLBW Infants
Primary: The Incidence of Early Onset Sepsis in VLBW Infants With AOP. — 18; 34; 7; 42 Participants
N/A N=62 Intelligent Control Approach to Anemia Management
End-Stage Renal Disease
Primary: Percent Hb 10-12 g/dL — 61.9; 72.5 Percent
N/A N=22 Does a Daily Iron Tablet Improve Anemia in Cystic Fibrosis
Cystic Fibrosis · Anemia, Iron-Deficiency
Primary: Change From Baseline in Hemoglobin Concentration (gm/dl) — 0.12; 0.09 gm/dl — p=0.81
Phase 2 N=74 Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Pregnant Women
Pregnancy
Primary: Percentage of Women Who Achieve Anemia Correction After a Single Dose of 1000mg of Low Molecular Weight Iron Dextran(INfeD). — 35; 11 Participants
N/A N=441 Anemia Management in Chronic Kidney Disease Not on Dialysis Patients After the European Renal Best Practice (ERBP) Working Group Recommendations
ANEMIA
Primary: % Patients Achieving Target Hemoglobin Levels — 42.5; 35.3 percentage of participants
Phase 3 N=2,018 Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients
Anemia
Primary: Evaluate the Safety of the Maximum Administered Dose, 15 mg/kg (up to a Maximum 1,000 mg) of FCM Compared to SMC. — 6; 22 participants
Phase 4 N=154 Clinical Evaluation of Iron Treatment Efficiency Among Non-anemic But Iron-deficient Female Blood Donors
Fatigue · Iron Deficiency
Primary: Level of Fatigue Before and After Iron Treatment/Placebo, Using a 10 Point Visual Analogue Scale. — 3.4; 3.5 centimeter — p=0.69
Phase 3 N=703 Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia
Anemia
Primary: Safety, as Defined by the Occurence of Serious Adverse Events (SAE's), of FCM Compared to SMC — 17; 11 participants
Phase 4 N=38 Intravenous Iron for Iron-deficiency Anemia in Pregnancy: a Randomized Controlled Trial
Iron Deficiency Anemia of Pregnancy · Iron Malabsorption
Primary: Maternal Anemia at Delivery — 4; 11 Participants — p=0.039
Phase 3 N=40 Heme Iron Polypeptide for Iron Deficiency Anemia in Chronic Renal Failure
Anemia · Renal Failure
Primary: Hemoglobin Concentration at 6 Months — 117; 113 g/L
N/A N=150 IV Iron for the Anemia of Traumatic Critical Illness
Trauma · ICU Anemia
Primary: RBC Transfusion — 47; 55 participants
Phase 3 N=270 A Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.
Haematopoiesis
Primary: Change From Baseline in Hemoglobin (Hb) After 8 Weeks of Treatment in Each Ferrous Bisglycinate Chelate Group (1 Tablet Daily and 2 Tablets Daily) — 2.6; 2.8 Gram per…
N/A N=56 Evaluation of Natureheme-iron on Iron Absorption Effect and Anti-oxidation Functions
Anemia
Primary: The Hemoglobin of the Subjects at Baseline and 6 Weeks — 0.38; 0.29; 0.57 g/dl
Phase 3 N=160 Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia
Anemia
Primary: The Number of Subjects Who Reported Treatment-emergent Adverse Events (AE's) — 60; 59 participants
Phase 3 N=735 Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia
Anemia
Primary: Number of Participants With Treatment-emergent Serious Adverse Events (SAE's) — 5; 9 participants
Phase 2 N=15 Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)
Anaemia
Primary: Percentage of Fractional Oral Iron Absorption Following Treatment With Daprodustat and rhEPO — 20.64; 20.62 Percentage (%) of iron absorbed — p=0.9971
Phase 4 N=13 Alternate Day Versus Daily Oral Iron Therapy in Adolescents
Iron Deficiency Anemia · Heavy Menstrual Bleeding · Abnormal Uterine Bleeding
Primary: Percentage of Eligible Patients Enrolled. — 13 Participants
N/A N=60 Total Dose Infusion of Ferumoxytol(1020mg) in 15 Minutes for Iron Deficiency Anemia
Iron Deficiency Anemia
Primary: Efficacy of 1020 mg of Ferumoxytol Over 15 Minutes. Hemoglobin Measurements Will Take Place at Four and Eight Week Visit. — 85; 58; 92; 86 percentage of participants
Phase 3 N=150 Randomized Trial of Iron Supplementation to Prevent Anemia in Very-low-birth-weight Infants
Anemia
Primary: Hematocrit (Hct) — 29.2; 28.3 percentage of red blood cells in blood
Phase 2 N=6 Evaluating the Safety and Effectiveness of Decitabine in People With Thalassemia Intermedia
Thalassemia
Primary: Number of Evaluable Patients With an Increase From Baseline in Hemoglobin (Hb) of ≥1.5 g/dL — 2 participants
Phase 3 N=836 Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis
Anemia · End Stage Renal Disease (ESRD)
Primary: Change From Baseline (BL) to the Average Hemoglobin (Hb) in Weeks 28-36 Without Rescue Therapy [EU (EMA)] — 0.428; 0.193 g/dL — p=<0.001
Phase 3 N=594 Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia
Anemia
Primary: Incidence of Treatment-emergent Adverse Events During Each 7-day Study Period — 174; 114 participants